1860P Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)

Research output: Contribution to journalMeeting abstract (Journal)

Abstract

Background: Limited knowledge currently exists on NCF in advanced cancer survivors treated with ICB. Here, we present the baseline data of an ongoing prospective trial regarding objective and subjective NCF. Methods: Patients (pts) followed-up at a single center, diagnosed with stage III/IV cancer of any type, who initiated ICB at least one year prior to and were in complete remission (CR) at time of inclusion, were invited to participate. Objective NCF was assessed using the test battery COGBAT®. Neurocognitive impairment (NCI) was defined by the International Cancer and Cognition Taskforce guidelines and deficits per subtest as 1.5 standard deviation below the normative mean. Subjective NCF, anxiety, depression and fatigue were assessed respectively through the Cognitive Failures Questionnaire, Hospital Anxiety and Depression Scale, and Fatigue Severity Scale. Results: From July 2022 to April 2023, 58 pts were enrolled (48 melanoma, 6 non-small cell lung carcinoma, 2 colon cancer, 1 renal cell carcinoma, 1 bladder cancer), median age was 64 y [34-92]); 34 male; 55 pts (95%) had stage IV disease; 12 pts (21%) had a history of brain metastasis. Median time since CR was 3.0 y [0.1-14.1]; median time since last ICB administration was 3.6 y [0.0-11.4]. We found objective NCI in 34 pts (59%), with deficits predominantly in memory (33%) and attention (31%) and in a lesser amount in executive functioning (16%). Moderate to severe subjective cognitive complaints were found in 12 pts (21%). Objective NCF only correlated significantly with age (r = -.782, p < .001) but not with subjective NCF, fatigue, anxiety, depression or a history of brain metastasis. Subjective NCF correlated significantly with anxiety, depression and fatigue (respectively r = .694, r = .454, r = .447, all p-values < .001). Conclusions: A majority of the advanced cancer survivors treated with ICB had objective NCI. A noteworthy lesser proportion had subjective cognitive complaints, indicating the need of neuropsychological assessment. Moderate to strong associations exist between subjective NCF and psychological distress, indicating the value of an integrative approach, including NCF remediation and psychosocial support when treating cognitive complaints.
Original languageEnglish
Article number1860P
Number of pages1
JournalAnnals of Oncology
Volume34
DOIs
Publication statusPublished - Oct 2023
EventESMO Congress - Madrid, Spain
Duration: 20 Oct 202324 Oct 2023

Fingerprint

Dive into the research topics of '1860P Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)'. Together they form a unique fingerprint.

Cite this